R01 CA114465/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2006	1
2008	5
2009	4
2010	9
2011	6
2012	8
2013	8
2014	3
2015	7
2016	5
2017	3
2018	1
2019	3
2024	0

1

The quest to overcome resistance to EGFR-targeted therapies in cancer.

Chong CR, Jänne PA. Chong CR, et al. Nat Med. 2013 Nov;19(11):1389-400. doi: 10.1038/nm.3388. Epub 2013 Nov 7. Nat Med. 2013. PMID: 24202392 Free PMC article. Review.

2

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR. Thress KS, et al. Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4. Nat Med. 2015. PMID: 25939061 Free PMC article.

3

The impact of genomic changes on treatment of lung cancer.

Cardarella S, Johnson BE. Cardarella S, et al. Am J Respir Crit Care Med. 2013 Oct 1;188(7):770-5. doi: 10.1164/rccm.201305-0843PP. Am J Respir Crit Care Med. 2013. PMID: 23841470 Free PMC article. Review.

4

State of the art: Response assessment in lung cancer in the era of genomic medicine.

Nishino M, Hatabu H, Johnson BE, McLoud TC. Nishino M, et al. Radiology. 2014 Apr;271(1):6-27. doi: 10.1148/radiol.14122524. Radiology. 2014. PMID: 24661292 Free PMC article. Review.

5

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Engelman JA, Jänne PA. Engelman JA, et al. Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248. Clin Cancer Res. 2008. PMID: 18483355 Review.

6

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.

Sacher AG, Jänne PA, Oxnard GR. Sacher AG, et al. Cancer. 2014 Aug 1;120(15):2289-98. doi: 10.1002/cncr.28723. Epub 2014 Apr 17. Cancer. 2014. PMID: 24752335 Free PMC article. Review.

7

Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?

Cheng ML, Oxnard GR. Cheng ML, et al. Clin Cancer Res. 2019 Feb 1;25(3):899-900. doi: 10.1158/1078-0432.CCR-18-2368. Epub 2018 Sep 6. Clin Cancer Res. 2019. PMID: 30190372 Free PMC article.

8

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA. Ercan D, et al. Clin Cancer Res. 2015 Sep 1;21(17):3913-23. doi: 10.1158/1078-0432.CCR-14-2789. Epub 2015 May 6. Clin Cancer Res. 2015. PMID: 25948633 Free PMC article.

9

Imaging of lung cancer in the era of molecular medicine.

Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD. Nishino M, et al. Acad Radiol. 2011 Apr;18(4):424-36. doi: 10.1016/j.acra.2010.10.020. Epub 2011 Jan 28. Acad Radiol. 2011. PMID: 21277232 Free PMC article. Review.

10

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.

Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Sacher AG, et al. JAMA Oncol. 2016 Mar;2(3):313-20. doi: 10.1001/jamaoncol.2015.4482. JAMA Oncol. 2016. PMID: 26720421 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year